» Articles » PMID: 32531261

TDP-1/TDP-43 Potentiates Human α-Synuclein (HASN) Neurodegeneration in Caenorhabditis Elegans

Overview
Publisher Elsevier
Date 2020 Jun 13
PMID 32531261
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

TAR DNA binding protein (TDP-43) is a DNA/RNA binding protein whose pathological role in amyotrophic lateral sclerosis (ALS) and frontal temporal lobe dementia (FTLD) via formation of protein aggregates is well established. In contrast, knowledge concerning its interactions with other neuropathological aggregating proteins is poorly understood. Human α-synuclein (HASN) elicits dopaminergic neuron degeneration via protein aggregation in Parkinson's disease. HASN protein aggregates are also found in TDP-43 lesions and colocalize in Lewy Body Dementia (LBD). To better understand the interactions of TDP-43 and HASN, we investigated the effects of genetic deletion of tdp-1, the Caenorhabditis elegans ortholog of human TDP-43, as well as overexpression of TDP-43, in transgenic models overexpressing HASN and HASN. Tdp-1 deletion improved the posture, movement, and developmental delay observed in transgenic animals pan-neuronally overexpressing HASN, and attenuated the loss and impairment of dopaminergic neurons caused by HASN or HASN overexpression. Tdp-1 deletion also led to a decrease in protein level, mRNA level and aggregate formation of HASN in living animals. RNA-seq studies suggested that tdp-1 supports expression of lysosomal genes and decreases expression of genes involved in heat shock. RNAi demonstrated that heat shock proteins can mediate HASN neuropathology. Co-overexpression of both human TDP-43 and HASN resulted in locomotion deficits, shorter lifespan, and more severe dopaminergic neuron impairments compared to single transgenes. Our results suggest TDP-1/TDP-43 potentiates HASN mediated neurodegeneration in C. elegans. This study indicates a multifunctional role for TDP-1/TDP-43 in neurodegeneration involving HASN.

Citing Articles

Co-Aggregation of TDP-43 with Other Pathogenic Proteins and Their Co-Pathologies in Neurodegenerative Diseases.

Jiang L, Zhang X, Hu H Int J Mol Sci. 2024; 25(22).

PMID: 39596445 PMC: 11594478. DOI: 10.3390/ijms252212380.


Novel C. elegans models of Lewy body disease reveal pathological protein interactions and widespread miRNA dysregulation.

Li R, Huang X, Shen L, Zhang T, Liu N, Hou X Cell Mol Life Sci. 2024; 81(1):377.

PMID: 39212733 PMC: 11364739. DOI: 10.1007/s00018-024-05383-0.


Genetic modifiers of synucleinopathies-lessons from experimental models.

Lee R, Koh T Oxf Open Neurosci. 2024; 2:kvad001.

PMID: 38596238 PMC: 10913850. DOI: 10.1093/oons/kvad001.


Concomitant protein pathogenesis in Parkinson's disease and perspective mechanisms.

Han Y, He Z Front Aging Neurosci. 2023; 15:1189809.

PMID: 37181621 PMC: 10174460. DOI: 10.3389/fnagi.2023.1189809.


Heparan sulfate proteoglycans mediate prion-like α-synuclein toxicity in Parkinson's in vivo models.

Chen M, Vincent J, Ezeanii A, Wakade S, Yerigenahally S, Mor D Life Sci Alliance. 2022; 5(11).

PMID: 35790300 PMC: 9259873. DOI: 10.26508/lsa.202201366.